<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115881">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594632</url>
  </required_header>
  <id_info>
    <org_study_id>10242</org_study_id>
    <nct_id>NCT01594632</nct_id>
  </id_info>
  <brief_title>Safety,Effectiveness and Acceptability of Sino-implant II in DR</brief_title>
  <official_title>A Study to Evaluate the Contraceptive Effectiveness, Safety and Acceptability of Sino-implant II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FHI 360</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the contraceptive effectiveness of Sino-implant (II).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized trial to assess the contraceptive effectiveness of Sino-implant (II) and to
      compare levonorgestrel concentrations, safety and acceptability of Sino-implant (II) and
      Jadelle.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pearl Index over 4 years of use of Sino-implant (II)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pearl Index over 5 years of use of Sino-implant (II)</measure>
    <time_frame>5 years</time_frame>
    <description>Pearl Index over 5 years of use of Sino-implant (II) ; continuation &amp; reasons for discontinuation in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pearl Index over 5 years of use of Sino-implant (II)</measure>
    <time_frame>5 years</time_frame>
    <description>annual and cumulative probability of pregnancy during 5 years of use of Sino-implant (II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pearl Index over 5 years of use of Sino-implant (II)</measure>
    <time_frame>5 years</time_frame>
    <description>levonorgestrel concentrations measured by HPLC/MS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pearl Index over 5 years of use of Sino-implant (II)</measure>
    <time_frame>5 years</time_frame>
    <description>LNG concentrations and estimated PK parameters during the first 6 months of use in a sub-group of users; adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Jadelle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contraception using Jadelle implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sino-implant (II)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levonorgestrel containing subdermal contraceptive implant [Zarin, Femplant, Trust or Simplant]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jadelle</intervention_name>
    <description>LNG containing subdermal contraceptive implant</description>
    <arm_group_label>Jadelle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sino-implant (II)</intervention_name>
    <description>LNG containing subdermal contraceptive implant</description>
    <arm_group_label>Sino-implant (II)</arm_group_label>
    <other_name>Zarin, Femplant, Trust, Simplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:• In good general health

          -  Aged between 18 and 44 years, inclusive

          -  Not pregnant

          -  Not lactating

          -  Not wishing to become pregnant in the next five years

          -  Request long-acting reversible contraception

          -  If previously used injectable contraceptives for pregnancy prevention, be more than 9
             months since last injection of Depo-Provera and more than 3 months after the last
             injection of a combined injectable contraceptive

          -  If previously used LNG-containing oral pills or implants, be more than 1 week after
             last hormone intake or implant removal

          -  Be able to understand the information provided and to make personal decisions on
             participation

          -  Consent to participation and sign a consent form

          -  Agree and be able to return to the clinic for follow-up visits over five years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivian Brache, LIC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profamilia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profamilia</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 16, 2016</lastchanged_date>
  <firstreceived_date>October 13, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AE adverse event</keyword>
  <keyword>AIDS acquired immunodeficiency syndrome</keyword>
  <keyword>ALT (SGPT) alanine aminotransferase</keyword>
  <keyword>ART antiretroviral therapy</keyword>
  <keyword>AST (SGOT) aspartate aminotransferase</keyword>
  <keyword>DCF data collection forms</keyword>
  <keyword>DMC Data Monitoring Committee</keyword>
  <keyword>FDA (U.S.) Food and Drug Administration</keyword>
  <keyword>GCP Good Clinical Practice guidelines</keyword>
  <keyword>HB sAg Hepatitis B surface antigen</keyword>
  <keyword>ICH International Conference of Harmonization</keyword>
  <keyword>IND Investigational New Drug Application</keyword>
  <keyword>IRB Institutional Review Board</keyword>
  <keyword>IU International units</keyword>
  <keyword>mg milligram(s)</keyword>
  <keyword>mm3 cubic millimeter(s)</keyword>
  <keyword>PCR polymerase chain reaction</keyword>
  <keyword>SAE serious adverse event</keyword>
  <keyword>µg microgram</keyword>
  <keyword>ULN upper limit of the normal range</keyword>
  <keyword>WB Western Blot</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
